Navidea Biopharmaceuticals Company Profile (NYSEMKT:NAVB)

About Navidea Biopharmaceuticals (NYSEMKT:NAVB)

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSEMKT:NAVB
  • CUSIP: 63937X10
  • Web: N/A
Capitalization:
  • Market Cap: $73.84 million
  • Outstanding Shares: 160,376,000
Average Prices:
  • 50 Day Moving Avg: $0.48
  • 200 Day Moving Avg: $0.60
  • 52 Week Range: $0.26 - $1.16
P/E:
  • Trailing P/E Ratio: 0.9632
  • Foreward P/E Ratio: -15.35
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $21.6 million
  • Price / Sales: 3.42
  • Book Value: $0.14 per share
  • Price / Book: 3.41
Profitability:
  • EBIDTA: ($1,140,000.00)
Misc:
  • Average Volume: 784,748 shs.
  • Short Ratio: 11.76
 

Frequently Asked Questions for Navidea Biopharmaceuticals (NYSEMKT:NAVB)

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) released its earnings results on Wednesday, March, 29th. The company reported ($0.02) earnings per share for the quarter. The business earned $3.36 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.

Who are some of Navidea Biopharmaceuticals' key competitors?

Who owns Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.09%), Harel Insurance Investments & Financial Services Ltd. (0.50%), Geode Capital Management LLC (0.46%), Spark Investment Management LLC (0.32%), California Public Employees Retirement System (0.24%) and Goldman Sachs Group Inc. (0.22%). Company insiders that own Navidea Biopharmaceuticals stock include Brent L Larson, Gordon A Troup and Jed Latkin. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

Who sold Navidea Biopharmaceuticals stock? Who is selling Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for Navidea Biopharmaceuticals.

Who bought Navidea Biopharmaceuticals stock? Who is buying Navidea Biopharmaceuticals stock?

Navidea Biopharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Spark Investment Management LLC, HighTower Advisors LLC and Morgan Stanley. Company insiders that have bought Navidea Biopharmaceuticals stock in the last two years include Gordon A Troup and Jed Latkin. View Insider Buying and Selling for Navidea Biopharmaceuticals.

How do I buy Navidea Biopharmaceuticals stock?

Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Navidea Biopharmaceuticals stock cost?

One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.46.

Analyst Ratings

Consensus Ratings for Navidea Biopharmaceuticals (NYSEMKT:NAVB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Earnings by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Earnings History by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2017Q4 2016($0.02)$3.36 millionViewN/AView Earnings Details
8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/AView Earnings Details
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.06)$0.90 million$0.75 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Current Year EPS Consensus Estimate: $-0.0800 EPS
Next Year EPS Consensus Estimate: $-0.0300 EPS

Dividends

Dividend History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Institutional Ownership by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.55View SEC Filing  
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.00View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.00View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Latest Headlines for Navidea Biopharmaceuticals (NYSEMKT:NAVB)
Source:
DateHeadline
americanbankingnews.com logoNavidea Biopharmaceuticals Inc (NAVB) CFO Acquires $11,411.55 in Stock
www.americanbankingnews.com - May 23 at 8:35 PM
finance.yahoo.com logoNavidea pays former CEO $618,000 after losing arbitration over his firing
finance.yahoo.com - May 16 at 6:28 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals reports Q1 earnings $0.53/shr
www.reuters.com - May 12 at 12:15 AM
finance.yahoo.com logoEdited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT
finance.yahoo.com - May 10 at 11:51 PM
bizjournals.com logoNavidea proposes 20-1 reverse stock split to prop up sagging shares
www.bizjournals.com - May 9 at 6:23 PM
finance.yahoo.com logoNavidea Biopharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 6:23 PM
bizjournals.com logoBiotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences
www.bizjournals.com - May 9 at 11:37 AM
americanbankingnews.com logoNavidea Biopharmaceuticals (NAVB) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 27 at 3:28 PM
finance.yahoo.com logoNavidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
finance.yahoo.com - April 25 at 6:01 PM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 6:48 PM
finance.yahoo.com logoNavidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
finance.yahoo.com - April 7 at 11:26 AM
finance.yahoo.com logoETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 11:26 AM
reuters.com logoBRIEF-Navidea Q4 loss per share $0.02
www.reuters.com - March 29 at 7:25 PM
us.rd.yahoo.com logoNavidea Provides Corporate Update and Reports Full Year 2016 Results
us.rd.yahoo.com - March 29 at 7:25 PM
bizjournals.com logoNavidea halved losses in 2016, projects positive cash flow in 2017
www.bizjournals.com - March 29 at 7:25 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals files for non timely 10-K
www.reuters.com - March 17 at 12:31 AM
bizjournals.com logoWhy Navidea’s looking ahead to entrepreneurial life after deal
www.bizjournals.com - March 10 at 9:36 AM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mat
biz.yahoo.com - March 9 at 8:29 AM
finance.yahoo.com logoNavidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health
finance.yahoo.com - March 3 at 6:44 PM
bizjournals.com logoNavidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens
www.bizjournals.com - March 3 at 6:44 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 2 at 6:58 PM
streetinsider.com logoNavidea Biopharma (NAVB) Reports CRG to Sell Stock of Macrophage Owned by Company - StreetInsider.com
www.streetinsider.com - February 24 at 4:09 PM
streetinsider.com logoUPDATE: Navidea Biopharma (NAVB) Reports Settlement ... - StreetInsider.com
www.streetinsider.com - February 23 at 11:51 PM
streetinsider.com logoUPDATE: Navidea Biopharma (NAVB) Reports Settlement Agreement with CRG Allowing Close of Cardinal Transaction
www.streetinsider.com - February 23 at 6:50 PM
reuters.com logoBRIEF-Navidea Biopharmaceuticals says reaches settlement with CRG relating to loan agreement
www.reuters.com - February 23 at 6:50 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 6:20 PM
biz.yahoo.com logoNAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 10 at 7:41 PM

Social

This page was last updated on 5/25/2017 by MarketBeat.com Staff